Delayed fractional dosing with RTS, S/AS01 improves humoral immunity to malaria via a balance of polyfunctional NANP6-and Pf16-specific antibodies

J Das, JK Fallon, CY Timothy, A Michell, TJ Suscovich… - Med, 2021 - cell.com
Background Malaria remains a key cause of mortality in low-income countries. RTS, S/AS01
is currently the most advanced malaria vaccine, demonstrating∼ 50% efficacy in controlled …

Antibody targets and properties for complement-fixation against the circumsporozoite protein in malaria immunity

L Kurtovic, DR Drew, AE Dent, JW Kazura… - Frontiers in …, 2021 - frontiersin.org
The Plasmodium falciparum circumsporozoite protein (CSP) forms the basis of leading
subunit malaria vaccine candidates. However, the mechanisms and specific targets of …

Complement in malaria immunity and vaccines

L Kurtovic, MJ Boyle, DH Opi, AT Kennedy… - Immunological …, 2020 - Wiley Online Library
Developing efficacious vaccines for human malaria caused by Plasmodium falciparum is a
major global health priority, although this has proven to be immensely challenging over the …

Acquisition of complement fixing antibodies targeting Plasmodium falciparum merozoites in infants and their mothers in Uganda

SE Mortazavi, A Lugaajju, M Nylander… - Frontiers in …, 2023 - frontiersin.org
Background Antibody-mediated complement fixation has previously been associated with
protection against malaria in naturally acquired immunity. However, the process of early-life …

Advancements and challenges in developing malaria vaccines: Targeting multiple stages of the parasite life cycle

Rajneesh, R Tiwari, VK Singh, A Kumar… - ACS Infectious …, 2023 - ACS Publications
Malaria, caused by Plasmodium species, remains a major global health concern, causing
millions of deaths annually. While the introduction of the RTS, S vaccine has shown promise …

Correlates of malaria vaccine efficacy

DI Stanisic, MBB McCall - Expert Review of Vaccines, 2021 - Taylor & Francis
Introduction: An effective vaccine against malaria forms a global health priority. Both
naturally acquired immunity and sterile protection induced by irradiated sporozoite …

Background malaria incidence and parasitemia during the three-dose RTS, S/AS01 vaccination series do not reduce magnitude of antibody response nor efficacy …

GJ Bell, S Gyaase, V Goel, B Adu, B Mensah… - BMC Infectious …, 2023 - Springer
Abstract Background RTS, S/AS01 has been recommended by WHO for widespread
implementation in medium to high malaria transmission settings. Previous analyses have …

Multi-functional antibody profiling for malaria vaccine development and evaluation

DH Opi, L Kurtovic, JA Chan, JL Horton… - Expert Review of …, 2021 - Taylor & Francis
Introduction A vaccine would greatly accelerate current global efforts toward malaria
elimination. While a partially efficacious vaccine has been achieved for Plasmodium …

[HTML][HTML] Serology for Plasmodium vivax surveillance: a novel approach to accelerate towards elimination

Y Tayipto, Z Liu, I Mueller, RJ Longley - Parasitology International, 2022 - Elsevier
Plasmodium vivax is the most widespread causative agent of human malaria in the world.
Despite the ongoing implementation of malaria control programs, the rate of case reduction …

Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique

L Sanchez, M Vidal, C Jairoce, R Aguilar, I Ubillos… - npj Vaccines, 2020 - nature.com
Abstract The RTS, S/AS01E vaccine has shown consistent but partial vaccine efficacy in a
pediatric phase 3 clinical trial using a 3-dose immunization schedule. A fourth-dose 18 …